Lilly: Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight
Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing. read more
Read full article »
Lilly is a Massachusetts-based pharmaceutical company that develops, produces and markets pharmaceutical products for healthcare professionals, patients and consumers.
Read more